The Economic and Epidemiological Impact of Focusing Voluntary Medical Male Circumcision for HIV Prevention on Specific Age Groups and Regions in Tanzania

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Background

Since its launch in 2010, the Tanzania National Voluntary Medical Male Circumcision (VMMC) Program has focused efforts on males ages 10–34 in 11 priority regions. Implementers have noted that over 70% of VMMC clients are between the ages of 10 and 19, raising questions about whether additional efforts would be required to recruit men age 20 and above. This analysis uses mathematical modeling to examine the economic and epidemiological consequences of scaling up VMMC among specific age groups and priority regions in Tanzania.

Methods and Findings

Analyses were conducted using the Decision Makers’ Program Planning Tool Version 2.0 (DMPPT 2.0), a compartmental model implemented in Microsoft Excel 2010. The model was populated with population, mortality, and HIV incidence and prevalence projections from external sources, including outputs from Spectrum/AIDS Impact Module (AIM). A separate DMPPT 2.0 model was created for each of the 11 priority regions. Tanzania can achieve the most immediate impact on HIV incidence by circumcising males ages 20–34. This strategy would also require the fewest VMMCs for each HIV infection averted. Circumcising men ages 10–24 will have the greatest impact on HIV incidence over a 15-year period. The most cost-effective approach (lowest cost per HIV infection averted) targets men ages 15–34. The model shows the VMMC program is cost saving in all 11 priority regions. VMMC program cost-effectiveness varies across regions due to differences in projected HIV incidence, with the most cost-effective programs in Njombe and Iringa.

Conclusions

The DMPPT 2.0 results reinforce Tanzania’s current VMMC strategy, providing newfound confidence in investing in circumcising adolescents. Tanzanian policy makers and program implementers will continue to focus scale-up of VMMC on men ages 10–34 years, seeking to maximize program impact and cost-effectiveness while acknowledging trends in demand among the younger and older age groups.

Related collections

Most cited references 9

Record: found
Abstract: found
Article: found

Is Open Access

Voluntary Medical Male Circumcision: Modeling the Impact and Cost of Expanding Male Circumcision for HIV Prevention in Eastern and Southern Africa

Emmanuel Njeuhmeli, Steven Forsythe, Jason Reed … (2011)

Introduction Three randomized controlled trials have shown that voluntary medical male circumcision (VMMC) reduces heterosexual HIV acquisition in men by up to 60% [1]–[3]. On the basis of these trial results, the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) now recommend that VMMC be offered to heterosexual men in combination with other effective HIV risk reduction interventions in settings with generalized HIV epidemics and where a substantial proportion of men are not circumcised [4]. The long-term population-level impact of implementing and scaling up VMMC services is expected to be considerable in terms of HIV infections averted, as well as net savings associated with the reduced need for treatment, care, and support of infected individuals. Previous model-based studies estimated that VMMC scale-up in countries with generalized HIV epidemics could result in substantial reductions in HIV transmission and prevalence over time among both men and women [3],[5]–[9]. A recent review of these studies concluded that one HIV infection could be averted for every five to 15 VMMCs performed [10]. Modeling studies also have found that expansion of VMMC services produces net savings when compared to lifetime HIV treatment costs [8],[9],[11]. In addition, studies have shown VMMC to be protective against some other sexually transmitted infections (STIs) in both men and women. VMMC has been found to reduce the risk of herpes simplex virus-2 in men [12] and human papillomavirus in men [12]–[15] and their female partners [16], and is associated with a reduction in the risk of genital ulcer disease [3],[17] and genital cancers [18]–[20] in both men and women. In light of this evidence, in early 2007, WHO and UNAIDS identified the following priority countries for VMMC scale-up: Botswana, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe, and Nyanza Province in Kenya (Figure 1). Four years later, most of these 13 countries have developed plans for VMMC scale-up and are at various stages of program implementation. However, with a few exceptions (e.g., Nyanza Province in Kenya and the Iringa Region in Tanzania), progress in expanding VMMC services remains slow [21]. 10.1371/journal.pmed.1001132.g001 Figure 1 Geographic distribution of HIV and male circumcision prevalence. For the 13 countries included in the study, the map on the left indicates the prevalence of HIV in adults ages 15 to 49 y. The map on the right indicates the percentage of men who are circumcised. There is consensus that VMMC scale-up will require substantial funding and massive efforts to adequately train personnel, equip facilities, and ensure the regular distribution of necessary commodities—mostly in settings with weak health systems and resource constraints. As background for the scale-up of safe VMMC, WHO, UNAIDS, and collaborating partners have developed a number of guidelines and toolkits, including a recommended minimum package of VMMC services [22] and clinical guidelines for the provision of these services [23]. In addition, to facilitate a more rapid scale-up of safe VMMC, WHO has outlined considerations for models to optimize the volume and efficiency (MOVE) of VMMC services [24]. Central to these considerations is the efficient use of facility space through the dedication of multiple surgical beds to one surgical team and the coordination of client flow; the efficient use of staff time through task shifting and task sharing, including deployment of non-physicians to complete all or specific steps in VMMC surgery; and the bundling of commodities and supplies required to perform VMMC, including consumable materials and surgical instruments [24]. To support decision making and planning for VMMC scale-up, the United States Agency for International Development (USAID) Health Policy Initiative collaborated with UNAIDS to develop the Decision Makers' Program Planning Tool (DMPPT) [25]. This modeling tool, which has been reviewed by an expert panel [10], allows analysts and decision makers to estimate the epidemiologic impact and cost of alternative programmatic options for scaling up VMMC. The objective of this study is to estimate the country-specific epidemiologic impact and the cost and net savings associated with scaling up VMMC services based on MOVE considerations in the 13 priority countries in eastern and southern Africa. The perspective that is taken is that of governments and their international partners in their roles as health program funders. To do this, we run country-specific DMPPT models and explore how the results for each country vary by VMMC effectiveness, VMMC coverage level, time to scale-up, level of post-circumcision behavior change, VMMC unit cost, and antiretroviral therapy (ART) cost. This study expands on previous related work [8],[9],[11] in several ways. All of our analyses are country-specific and based on the most recent data on HIV and male circumcision prevalence available. Our calculations provide more comprehensive estimates of VMMC-related costs than was the case in previous studies since they include costs for supply chain management and waste management, as per WHO's recent recommendations for efficient VMMC scale-up [24]. In addition, we provide country-specific results on impact (VMMC per HIV infection averted), cost-effectiveness (cost per HIV infection averted) and cost savings (cost of VMMC relative to the averted cost of lifetime provision of ART). Methods The Model The DMPPT is a Microsoft-Excel-based modeling tool that estimates the epidemiologic impact (HIV infections averted) and the cost and net savings associated with different programming scenarios for VMMC scale-up. A list of all the equations used in the model can be found in Table S1. Additional details, including a copy of the workbook and the model manual [25], can be found at http://www.malecircumcision.org/programs/DMPPT.html. The DMPPT is a compartmental deterministic model in which the population is disaggregated into four sex/age groups (females ages 15–24 y, males ages 15–24 y, females ages 25–49 y, and males ages 25–49 y). For each population group, a susceptible and infected population is described [26],[27]. The susceptible population is increased by people aging into it (15-y-olds entering the younger age group and 25-y-olds leaving the younger age group and entering the older age group) and decreased by non-AIDS deaths and new infections. The infected population is increased by new infections and decreased by non-AIDS deaths, AIDS deaths, and aging out. In the model, HIV incidence (the proportion of the susceptible population becoming infected each year) is the product of HIV prevalence in the population and the force of infection. The force of infection is determined by the base rate of infection (which is a fitting parameter specific to each population group), changes in behavior, and changes due to male circumcision. Changes in behavior are assumed to occur as the epidemic progresses because of two key influences. Individuals with the riskiest behaviors are assumed to become infected first and die sooner than the rest of the population. Also, as AIDS deaths accumulate, a powerful effect on individual behavior is assumed, as those who know someone who has died from AIDS are motivated to adopt safer behaviors. Thus, the force of infection can drop over time as the cumulative number of AIDS deaths increases. The amount of the effect is determined by a fitting parameter that produces the best fit to the historical HIV prevalence trend. The impact of other prevention interventions is incorporated through exogenous reductions in the force of infection. The effect of male circumcision on the force of infection is simply the increase in the prevalence of male circumcision multiplied by the reduction in susceptibility due to circumcision. For each scenario of interest, the DMPPT model generates two projections: a baseline projection, in which male circumcision coverage is held constant at the pre-scale-up level, and a scale-up projection where VMMC coverage is scaled up to the desired coverage level. In the baseline projection, new infections increase over time in response to the initial force of infection. This causes HIV prevalence to rise rapidly in early years. The force of infection then declines somewhat as AIDS deaths accumulate and prevalence stabilizes. Implementation of a male circumcision program can cause a further reduction in the force of infection (depending on the increase in male circumcision coverage), leading to a decline in new infections and HIV prevalence. There is some concern that men who undergo circumcision may develop a false sense of protection against HIV and thereafter decrease or even stop previously implemented protective behaviors [28],[29]. Post-circumcision behavior change is modeled in the DMPPT as a proportional change in the force of infection, with a VMMC scale-up scenario in which circumcision does not lead to any behavior change being modeled as having a 0% post-circumcision behavior change effect. The DMPPT model calculates the yearly cost of the additional circumcisions (the number of VMMCs required above and beyond those occurring at pre-scale-up coverage levels) as the sum of the additional circumcisions performed per annum times the VMMC unit cost. The model also calculates the net savings associated with HIV infections averted and the subsequent treatment costs averted. Demographic, Epidemiologic, and Sexual Behavior Data The demographic and epidemiologic inputs required to estimate the epidemiologic impact of VMMC scale-up include the following: Demographic data—size of adult population by sex and age group, adult population growth rate, crude birth rate, crude death rate, proportion of population surviving to age 15 y, pre-scale-up male circumcision prevalence. Epidemiologic data—HIV prevalence among adults by sex and age group; effectiveness of male circumcision in preventing HIV infection; underlying HIV transmission factors based on scientific evidence, including probability of transmission from mother to child; fertility reduction due to HIV. Sexual behavior data—sexual mixing patterns by sex and age group, post-circumcision behavior change (change in condom use and/or change in number of sexual partners following VMMC resulting from lowered perceived risk). We obtained the required demographic, epidemiologic, and sexual behavior data for each country from recent household surveys [30]–[42] and Spectrum, a modeling software package, which includes a demographic platform populated with UN population data [27],[43],[44]. Country-specific pre-scale-up population characteristics, including size of the adult population, adult population growth rate, male circumcision and adult HIV prevalence, and HIV incidence, are shown in Table 1. A complete listing of the data used for each country is available from the authors upon request. 10.1371/journal.pmed.1001132.t001 Table 1 Pre-scale-up population characteristics, by country. Country Population Aged 15–49 y (Millions) Adult Population Growth Rate (Percentage) Male Circumcision Prevalence (Percentage) Adult HIV Prevalence (Percentage) Adult HIV Incidence (Percentage) Botswana 1.08 2.42 10.2 22.9 2.0 Lesotho 1.06 1.34 0.0 23.6 2.9 Malawi 6.84 3.02 20.7 12.5 1.0 Mozambique 10.32 2.45 59.5 12.9 1.4 Namibia 1.09 2.22 21.0 14.1 0.8 Nyanza Province, Kenya 1.51 2.80 44.8 13.1 1.6 Rwanda 4.49 3.29 10.0 3.1 0.3 South Africa 26.84 0.89 44.7 16.9 2.1 Swaziland 0.59 1.51 8.2 26.4 3.2 Tanzania 19.63 2.89 66.8 6.7 0.8 Uganda 14.16 3.87 24.8 6.5 0.7 Zambia 6.85 2.61 10.8 14.9 1.6 Zimbabwe 6.19 1.50 10.3 17.9 2.2 Table 1 provides the size of the 2008 population aged 15–49 y, adult population growth rate, and adult HIV incidence from Spectrum, which is populated with UN population data [27],[43],[44]. The years for the pre-scale-up male circumcision and adult HIV prevalence data are as follows: Botswana (2004) [30], Lesotho (2004) [9],[39], Malawi (2004) [40], Mozambique (2003) [35], Namibia (2007) [38], Nyanza Province, Kenya (2008/2009) [36], Rwanda (2005) [9],[34], South Africa (2008), Swaziland (2006/2007) [32], Tanzania (2007/2008) [42], Uganda (2004) [37], Zambia (2007) [31], and Zimbabwe (2005/2006) [33]. Cost Data A breakdown of the VMMC unit cost used in the model is provided in Table 2. With the exception of the waste management and supply chain costs, the unit cost components are derived from a VMMC costing study conducted in Zimbabwe in 2010 as part of a multi-country study that also included Kenya, Namibia, South Africa, Uganda, and Zambia [45]–[50]. Zimbabwe was chosen because it is one of the first countries to scale up VMMC services following WHO's MOVE considerations for more efficient use of facility space and staff time and for the bundling of the commodities required to perform VMMC [24]. Information on required inputs and costs was collected from sites providing VMMC in Zimbabwe. This includes data on both direct costs (consumables, staff costs, and training costs) and indirect costs (capital costs, maintenance and utility costs, support overhead, and management overhead). Because significant variations in labor costs were noted across countries, we vary the staff costs by country, adjusting them by after tax median monthly disposable salary. We also adjust the costing information collected in the Zimbabwe study for underreporting on waste management and other supply chain costs [51]. We base the waste management costs on a costing analysis conducted in Swaziland, a detailed description of which is provided elsewhere [52]. The VMMC unit cost used for each country is shown in Table 3. 10.1371/journal.pmed.1001132.t002 Table 2 VMMC unit cost components. Category Cost Component Cost (US$) Direct costs Consumables 28.67 Waste management 9.39 Other supply chain 10.91 Staff costs Variablea Training costs 1.70 Indirect costs Capital costs 0.45 Maintenance and utility costs 3.24 Support overhead 4.42 Management overhead 2.32 Table 2 presents the components of the VMMC unit cost used in this study. The VMMC unit cost was derived based on a VMMC costing study conducted in Zimbabwe in 2010 [50] and supplemented with analysis of data from Swaziland. a We vary staff costs by country, adjusting them by after tax median monthly disposable salary. 10.1371/journal.pmed.1001132.t003 Table 3 VMMC unit cost by country. Country VMMC Unit Cost—Base Case (US$) VMMC Unit Cost Range (US$) Botswana 78.07 62.45–93.68 Lesotho 83.78 67.03–100.54 Malawi 83.78 67.03–100.54 Mozambique 86.29 69.03–103.55 Namibia 86.60 69.28–103.92 Nyanza Province, Kenya 74.89 59.92–89.87 Rwanda 80.13 64.10–96.16 South Africa 95.15 76.12–114.18 Swaziland 74.83 59.86–89.79 Tanzania 82.56 66.04–99.07 Uganda 65.85 52.68–79.02 Zambia 89.65 71.72–107.58 Zimbabwe 78.23 62.58–93.87 Table 3 shows the country-specific VMMC unit costs used in the study. To obtain the VMMC unit cost for each country, we vary staff costs in each country, adjusting them by after tax median monthly disposable salary [51]. The range used in the sensitivity analysis is country base case unit cost ±20%. For lifetime HIV treatment costs, we use the default discounted value in the DMPPT model (US$7,400) [25]; we use the same value for all countries. This value includes costs of AIDS treatment and care, including ART, treatment of major opportunistic infections, laboratory tests, and home-based care. The lifetime HIV treatment cost is based on a unit cost of US$155 for first-line antiretroviral drugs and US$1,678 for second-line antiretroviral drugs [53]. We also assume that need for treatment begins after 8 y of infection and that the annual continuation rate on ART is 97.5% [27]. Following common practice in economic evaluation, we apply an annual discount rate of 3% on future expenditures and savings [54] as well as on infections averted [55]. Base Case and Sensitivity Analysis Our analyses are limited to the scale-up of VMMC services among males ages 15 to 49 y who are HIV-negative. For all models, we assume that the scale-up begins in 2011 and that the pace of scale-up is slower at first, followed by a more rapid scale-up, and then another slow period of scale-up, to allow for training and other logistic developments likely to occur in the early stages of implementation. The model observation period for all models is 2011 to 2025. This allows us to evaluate the 15-y impact of VMMC more comprehensively. For the base case, we assume the following: VMMC effectiveness—we use 60% for the protective effect of VMMC and assume that the effect is constant over the model simulation period [1],[56]. Target VMMC coverage level—male circumcision coverage is increased from pre-scale-up levels to 80% of HIV-negative males ages 15 to 49 y. Time to 80% scale-up—male circumcision coverage is increased from pre-scale-up levels to 80% of HIV-negative males ages 15 to 49 in 5 y, with the coverage target reached by 2015 and maintained at 80% thereafter. Post-circumcision behavior change—no post-circumcision behavior change is associated with VMMC scale-up. VMMC unit cost—the VMMC unit cost used for each country is shown in Table 3. Given uncertainty in model inputs, we also conduct sensitivity analyses, exploring various alternative scenarios. We vary VMMC effectiveness, VMMC coverage level, time to scale-up, level of post-circumcision behavior change, VMMC unit cost, and lifetime HIV treatment cost as follows: VMMC effectiveness—34% and 77% (versus 60%) [1]. Target VMMC coverage levels—50% and 100% (versus. 80%). Time to 80% scale-up—1, 10, and 15 y (versus 5 y). Post-circumcision behavior change—a 30% post-circumcision behavior change effect is associated with MMC scale-up (versus no post-circumcision behavior change, or 0%). VMMC unit cost—country base case unit cost ±20% as shown in Table 3. Lifetime ART cost—ART cost is assumed to decline over time, leading to a lifetime cost of US$3,400 (versus US$7,400) [53]. Results Base Case—80% VMMC Coverage by 2015 The number of additional VMMCs required to achieve 80% male circumcision coverage by 2015 is presented in Table 4. A total of 20.34 million VMMCs are required to scale up male circumcision coverage to 80% by 2015 in Botswana, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe, and Nyanza Province in Kenya. When taking the longer-term view (to 2025), an additional 8.42 million VMMCs are required between 2016 and 2025, for a total of almost 29 million VMMCs in the model's full study period (2011–2025). The number of VMMCs needed to achieve 80% male circumcision by 2015 varies by country, with the largest number of VMMCs required in South Africa (the country with the largest population and a high adult HIV prevalence) followed by Uganda (the country with a large and fast-growing population and low baseline VMMC prevalence), Malawi, Zambia, and Zimbabwe (also countries low baseline VMMC prevalence). 10.1371/journal.pmed.1001132.t004 Table 4 Impact of VMMC on HIV infections averted in base case, by country, 2011–2015 and 2011–2025. Country Time Period Additional VMMCs (Millions) HIV Infections Averted (Millions) HIV Infections Averted (Percentage) VMMC per HIV Infection Averted Botswana 2011–2015 0.35 0.01 12 36 2011–2025 0.49 0.06 28 8 Lesotho 2011–2015 0.38 0.01 12 28 2011–2025 0.54 0.11 37 5 Malawi 2011–2015 2.10 0.03 11 66 2011–2025 3.04 0.24 28 13 Mozambique 2011–2015 1.06 0.03 5 38 2011–2025 1.53 0.22 13 7 Namibia 2011–2015 0.33 0.00 9 109 2011–2025 0.48 0.02 25 26 Nyanza Province, Kenya 2011–2015 0.38 0.01 6 36 2011–2025 0.57 0.07 16 8 Rwanda 2011–2015 1.75 0.01 10 239 2011–2025 2.53 0.06 29 44 South Africa 2011–2015 4.33 0.14 7 30 2011–2025 5.94 1.08 20 5 Swaziland 2011–2015 0.18 0.01 12 25 2011–2025 0.27 0.06 34 5 Tanzania 2011–2015 1.38 0.02 3 56 2011–2025 1.98 0.20 9 10 Uganda 2011–2015 4.25 0.05 10 91 2011–2025 6.35 0.34 25 19 Zambia 2011–2015 1.95 0.04 12 43 2011–2025 2.87 0.34 30 8 Zimbabwe 2011–2015 1.91 0.06 13 31 2011–2025 2.17 0.57 42 4 Total 2011–2015 20.34 0.43 8 47 2011–2025 28.76 3.36 22 9 Table 4 presents the additional VMMCs and the impact of VMMC on HIV infections averted for 2011–2015 and 2011–2025 for the base case scenario. HIV infections averted are not discounted. We find a strong impact of scaling up VMMC to achieve 80% coverage by 2015 on the number of adult HIV infections averted. A total of 430,000 HIV infections are averted in the 13 countries between 2011 and 2015, while almost 3.36 million HIV infections are averted by 2025 (Table 4). South Africa is the country with the largest number of HIV infections averted (with more than 1 million infections averted between 2011 and 2025) followed by Zimbabwe, Zambia, and Uganda. More than 20% of new HIV infections are averted between 2011 and 2025 in all countries except Mozambique, Nyanza Province (Kenya), South Africa, and Tanzania (the countries with the highest baseline VMMC prevalence). Zimbabwe is the country with the highest percentage of new HIV infections averted, with 42% of new infections averted between 2011 and 2025. The large benefit of VMMC in Zimbabwe is largely driven by the currently low prevalence of VMMC (10.3%) and high HIV prevalence (17.9%) and incidence (2.2%). The number of VMMCs required to avert one HIV infection is calculated by dividing the additional number of VMMCs required by the number of HIV infections averted over the relevant time period. For the period 2011–2015, the number of VMMCs per HIV infection averted ranges from 25 in Swaziland to 239 in Rwanda, while for the full study period (2011–2025), the number of VMMCs per HIV infection averted ranges from four in Zimbabwe to 44 in Rwanda (Table 4). For the period 2011–2025, the number of VMMCs per HIV infection averted is ten or less in all countries except Malawi, Namibia, Rwanda, and Uganda, each of which has a relatively low incidence of HIV. Although circumcision of HIV-infected men has not been found to directly reduce HIV transmission to their female partners [57], and the primary impact of increasing VMMC coverage is to reduce the number of new HIV infections in men, the number of new infections in women is also reduced. This occurs by reducing the exposure of women to HIV-infected men. That is, as HIV incidence decreases in men following VMMC scale-up, the probability of women encountering infected male partners decreases, with a consequent reduction in HIV incidence among women. The HIV infections averted (presented in Table 4) thus represent infections averted in both men and women. Figure 2 illustrates the male and female HIV infections averted over time, by country, for 2011–2025. In all countries, the cumulative number of male HIV infections averted between 2011 and 2025 is higher than the cumulative number of female HIV infections averted. In the early years, the HIV infections averted occur mostly among men, but over time, the proportion of HIV infections averted in women steadily increases, with new HIV infections averted in women representing almost half of the total HIV infections averted in 2025. 10.1371/journal.pmed.1001132.g002 Figure 2 HIV infections averted in base case, by male and female, by country, 2011–2025. Figure 2 provides data for males and females for 2011–2025 for the base case scenario in which 80% coverage of VMMC is reached in 2015 and maintained thereafter, and there is no post-circumcision risk behavior change. Figure 3 shows the discounted cost of scaling up VMMC to achieve 80% coverage by 2015 for each of the 13 priority countries for the period 2011–2015. The cost ranges from US$12.53 million in Swaziland (the country with the smallest number of additional VMMCs required) to US$376.55 million in South Africa (the country with the highest number of additional VMMCs required), with a total of US$1,520,000,000 needed to scale up VMMC coverage to 80% in the 13 countries by 2015. The cost for the period 2011–2025 is shown in the first column of Table 5. A total of over US$2,000,000,000 is needed to scale up VMMC coverage to 80% by 2015 and maintain this level of coverage in the 13 countries until 2025. 10.1371/journal.pmed.1001132.g003 Figure 3 Cost for scaling up VMMC coverage in base case, by country, 2011–2015. Figure 3 provides the discounted cost of scaling up VMMC coverage for 2011–2015 for the base case scenario in which 80% coverage of VMMC is reached in 2015 and maintained thereafter, and there is no post-circumcision risk behavior change. 10.1371/journal.pmed.1001132.t005 Table 5 Total cost and net savings per HIV infection averted for base case scenario, by country, 2011–2025. Country Cost of VMMC Scale-Up, 2011–2025 (US$ Millions) Cost per HIV Infection Averted, 2011–2025 (US$) Net Savings, 2011–2025 (US$ Millions) Net Savings per HIV Infection Averted, 2011–2025 (US$) Botswana 32.79 693 317.14 6,707 Lesotho 34.97 442 550.57 6,958 Malawi 218.46 1,216 1,110.98 6,184 Mozambique 113.32 704 1,077.25 6,696 Namibia 35.52 2,558 67.21 4,842 Nyanza Province, Kenya 36.38 660 371.23 6,740 Rwanda 173.78 4,096 140.21 3,304 South Africa 489.47 605 5,498.55 6,795 Swaziland 17.18 406 295.88 6,994 Tanzania 140.40 950 953.74 6,450 Uganda 357.29 1,408 1,520.36 5,992 Zambia 220.42 869 1,679.41 6,623 Zimbabwe 153.84 369 2,930.64 7,031 Total 2,023.80 809 16,513.15 6,608 Table 5 provides the discounted cost of scaling up VMMC coverage, cost per HIV infection averted, and net savings per HIV infection averted for 2011–2025 for the base case scenario. HIV infections averted are discounted. Combining the cost data with the number of HIV infections averted, we obtain the discounted cost per HIV infection averted. The cost per HIV infection averted for the period 2011–2025 ranges from US$369 in Zimbabwe, where adult HIV prevalence is 17.9%, to US$4,096 in Rwanda, where adult HIV prevalence is lower than in any of the other 13 countries studied (3.1%). The overall cost per HIV infection averted for 2011–2025 for all 13 countries is US$809. Finally, we calculate the net savings associated with VMMC scale-up. The savings due to future ART costs avoided (with the discounted value of lifetime HIV treatment costs estimated at US$7,400 per infection) minus the discounted VMMC costs amount to US$16,510,000,000 for the 13 countries from 2011 to 2025 (Table 5). The net savings can also be combined with the number of HIV infections averted to obtain the net savings per HIV infection averted. For 2011–2025, this value ranges from US$3,304 in Rwanda to US$7,031 in Zimbabwe. The overall net savings per HIV infection averted for 2011–2025 for all 13 countries is US$6,608. Sensitivity Analysis Table 6 presents the results of the sensitivity analysis. The table provides the values for the HIV infections averted, the number of VMMCs per HIV infection averted, the cost per HIV infection averted, and the net savings per HIV infection averted for 2011–2025 for each parameter examined. The values for the base scenario (80% male circumcision coverage within 5 y) are shown in the third column of Table 6. 10.1371/journal.pmed.1001132.t006 Table 6 Sensitivity analysis of key parameters (2011–2025). Country Results from DMPPT Base Case Scenario VMMC Effectiveness VMMC Coverage Time to Scale-Up BC 30%a Cost per VMMC ART Cost = US$3,400 34% 77% 50% 100% 1 y 10 y 15 y −20% Base Case Cost +20% Base Case Cost Botswana IA 62,773 34,504 82,029 35,620 80,877 75,952 45,226 30,171 62,773 62,773 62,773 62,773 VMMC per IA 8 14 6 8 8 7 10 14 8 8 8 8 Cost per IA (US$) 693 1,253 533 694 694 605 881 1,197 836 555 832 693 Net savings per IA (US$) 6,707 6,147 6,867 6,706 6,706 6,795 6,519 6,203 6,564 6,845 6,568 2,707 Lesotho IA 106,427 60,123 132,245 66,385 129,578 130,568 73,664 46,994 100,848 106,427 106,427 106,427 VMMC per IA 5 9 4 5 5 4 7 10 5 5 5 5 Cost per IA (US$) 442 777 356 440 454 382 579 816 466 354 530 442 Net savings per IA (US$) 6,958 6,623 7,044 6,960 6,946 7,018 6,821 6,584 6,934 7,046 6,870 2,958 Malawi IA 240,685 131,912 315,299 121,012 317,639 292,121 172,169 113,722 172,576 240,685 240,685 240,685 VMMC per IA 13 23 10 12 13 11 16 23 18 13 13 13 Cost per IA (US$) 1,216 2,210 930 1,194 1,233 1,064 1,543 2,100 1,696 973 1,459 1,216 Net savings per IA (US$) 6,184 5,190 6,470 6,206 6,167 6,336 5,857 5,300 5,704 6,427 5,941 2,184 Mozambique b IA 215,861 103,714 314,141 421,592 262,897 153,291 100,400 159,030 215,861 215,861 215,861 VMMC per IA 7 14 5 7 6 9 13 10 7 7 7 Cost per IA (US$) 704 1,440 491 714 615 900 1,235 954 563 845 704 Net savings per IA (US$) 6,696 5,960 6,909 6,686 6,785 6,500 6,165 6,446 6,837 6,555 2,696 Namibia IA 18,373 9,936 24,335 9,243 24,174 23,160 12,520 7,924 12,947 18,373 18,373 18,373 VMMC per IA 26 48 20 25 26 21 36 53 37 26 26 26 Cost per IA (US$) 2,558 4,741 1,929 2,502 2,601 2,134 3,453 4,955 3,629 2,047 3,070 2,558 Net savings per IA (US$) 4,842 2,659 5,471 4,898 4,799 5,266 3,947 2,445 3,771 5,353 4,330 842 Nyanza Province, Kenya IA 73,420 35,776 105,322 2,382 72,961 53,834 32,309 21,649 31,567 44,636 44,636 73,420 VMMC per IA 8 16 5 8 8 7 10 13 11 8 8 8 Cost per IA (US$) 660 1,337 465 661 661 585 820 1,089 933 528 793 660 Net savings per IA (US$) 6,740 6,063 6,935 6,739 6,739 6,815 6,580 6,311 6,467 6,872 6,607 2,740 Rwanda c IA 56,840 32,138 72,988 33,163 72,039 68,999 40,514 26,480 (1,183) 56,840 56,840 56,840 VMMC per IA 44 79 35 43 45 38 58 81 (2,132) 44 44 44 Cost per IA (US$) 4,096 7,248 3,188 4,015 4,152 3,594 5,195 7,118 (192,148) 3,276 4,915 4,096 Net savings per IA (US$) 3,304 152 4,212 3,385 3,248 3,806 2,205 282 N.A. 4,124 2,485 (696) South Africa IA 1,083,869 553,267 1,496,933 164,840 1,677,803 1,340,315 750,846 478,788 954,426 1,083,869 1,083,869 1,083,869 VMMC per IA 5 11 4 5 6 5 7 11 6 5 5 5 Cost per IA (US$) 605 1,161 444 595 614 518 798 1,135 685 484 726 605 Net savings per IA (US$) 6,795 6,239 6,956 6,805 6,786 6,882 6,602 6,265 6,715 6,916 6,674 2,795 Swaziland IA 56,810 31,886 71,520 33,356 70,597 69,466 39,535 25,032 53,234 56,810 56,810 56,810 VMMC per IA 5 8 4 5 5 4 6 9 5 5 5 5 Cost per IA (US$) 406 717 323 401 418 366 534 755 436 325 487 406 Net savings per IA (US$) 6,994 6,683 7,077 6,999 6,982 7,034 6,866 6,645 6,964 7,075 6,913 2,994 Tanzania b IA 199,249 92,261 300,691 492,563 241,090 143,379 95,386 173,793 199,249 199,249 199,249 VMMC per IA 10 21 7 10 9 13 18 11 10 10 10 Cost per IA (US$) 950 2,035 633 967 838 1,190 1,600 1,090 760 1,139 950 Net savings per IA (US$) 6,450 5,365 6,767 6,433 6,562 6,210 5,800 6,310 6,640 6,261 2,450 Uganda IA 339,524 182,516 451,568 157,211 458,128 408,009 245,533 1,654,578 104,102 339,524 339,524 339,524 VMMC per IA 19 35 14 18 19 16 24 32 61 19 19 19 Cost per IA (US$) 1,408 2,615 1,060 1,387 1,422 1,250 1,755 2,322 4,589 1,126 1,690 1,408 Net savings per IA (US$) 5,992 4,785 6,340 6,013 5,978 6,150 5,645 5,078 2,811 6,274 5,710 1,992 Zambia IA 339,632 188,110 441,327 252,260 570,773 536,129 321,756 215,692 407,557 444,352 444,352 339,632 VMMC per IA 8 15 7 8 8 7 10 14 9 8 8 8 Cost per IA (US$) 869 1,560 671 865 874 769 1,082 1,440 948 695 1,043 869 Net savings per IA (US$) 6,531 5,840 6,729 6,535 6,526 6,631 6,318 5,960 6,452 6,705 6,357 2,531 Zimbabwe IA 565,749 311,075 691,348 320,894 686,019 699,894 375,010 231,007 520,864 565,751 565,751 565,749 VMMC per IA 4 7 3 4 4 3 6 9 4 4 4 4 Cost per IA (US$) 369 669 300 370 390 309 523 795 401 292 437 369 Net savings per IA (US$) 7,031 6,731 7,100 7,030 7,010 7,091 6,877 6,605 6,999 7,108 6,963 3,031 Table 6 presents sensitivity analysis for the following key parameters: VMMC effectiveness, VMMC coverage, time to scale-up, level of post-circumcision behavior change, VMMC unit cost, and lifetime HIV treatment cost. a BC is post-circumcision risk behavior change. b No models were run for the scale-up to 50% VMMC coverage scenario for Mozambique and Tanzania, since national pre-scale-up VMMC coverage in these two countries was greater than 50%. c Scaling up VMMC in the presence of 30% post-circumcision risk behavior change in Rwanda resulted in an increase in HIV infections. IA, infection(s) averted. The results help to confirm the internal consistency of the DMPPT model and show that, in large measure, the VMMC impact, cost, and savings results that we observe in the base case are robust to changes in VMMC effectiveness, VMMC coverage, time to scale-up, level of post-circumcision behavior change, VMMC unit cost, and lifetime HIV treatment cost. Our analysis varying VMMC effectiveness shows that even if we assume much reduced effectiveness (34% instead of 60%), high numbers of infections are averted and net savings per infection averted are obtained. The same is true if the VMMC coverage target is reduced from 80% to 50% or if the time to achieve 80% VMMC coverage is increased to 10 or 15 y. To assess the potential impact of post-circumcision risk behavior change, the model calculates the impact of risky sexual behaviors reverting to patterns that existed earlier in the epidemic, prior to the scale-up of VMMC services. It should be noted that this impact is different from the early resumption of sexual activity before complete wound healing that can also be an issue of concern in the context of expanding VMMC services. The impact is the result of behavior change due to a false perception that VMMC has eliminated the risk of HIV transmission. As compared to no post-circumcision risk behavior change, assuming 30% post-circumcision risk behavior change results in a decrease in the HIV infections averted, an increase in the numbers of VMMCs per HIV infection averted, an increase in the cost per HIV infection averted, and a decrease in net savings. In all of the countries studied except Rwanda, VMMC scale-up remains cost saving, even with 30% post-circumcision risk behavior change. In Rwanda, the country with the lowest HIV prevalence, scaling up VMMC in the presence of this level of post-circumcision risk behavior leads to an increase in the number of new HIV infections. Predictably, decreasing (increasing) the base case VMMC unit cost by 20% results in a decrease (increase) in the cost per HIV infection averted and an increase (decrease) in the net savings per HIV infection averted in countries. Assuming the lower VMMC unit cost for each country, the cost and net savings associated with scaling up VMMC coverage to 80% by 2015 and maintaining this level of coverage in the 13 countries until 2025 are US$1,620,000,000 and US$16,900,000,000 instead of US$2,020,000,000 and US$16,510,000,000 in the base case. Assuming the higher VMMC unit cost, the cost of scaling up VMMC services in the 13 countries is US$2,430,000,000, resulting in net savings of US$16,090,000,000. Reducing lifetime ART cost from US$7,400 to US$3,400 does significantly reduce the net savings per infection averted in all countries, although it remains well above US$2,000 in almost all countries. Rwanda is the only country where such a reduction in lifetime ART cost would lead to net losses per infection averted. Net savings associated with scaling up VMMC coverage is reduced to US$6,480,000,000 in the 13 countries if lifetime ART cost is US$3,400. Discussion To support decision making and planning for VMMC scale-up in Botswana, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe, and Nyanza Province in Kenya, we estimate the country-specific impact and cost of scaling up VMMC services using the DMPPT model developed by the USAID and UNAIDS. Our study suggests that rapid scale-up of VMMC in eastern and southern Africa is warranted based on the likely impact on the region's HIV epidemics and the resultant cost savings. Model results also show that, although the primary impact of scaling up VMMC coverage is to reduce the number of new HIV infections in men, the intervention also prevents HIV infections in women. While the cumulative number of male HIV infections averted between 2011 and 2025 is higher than the cumulative number of female HIV infections averted, the proportion of HIV infections averted in women steadily increases until HIV infections averted in women represent almost half of the new HIV infections averted in 2025. Our results show that the costs per infection averted are comparable to the estimated cost per infection averted of a number of key HIV prevention interventions implemented in the region. The cost per HIV infection averted, which ranges from US$369 in Zimbabwe to US$4,096 in Rwanda, is below US$1,000 in all countries except Malawi, Namibia, Rwanda, and Uganda. These costs per infection averted are comparable to those of prevention of vertical transmission (US$663 per HIV-positive birth averted), voluntary counseling and testing (US$1,315 per HIV infection averted), and prevention of STIs (US$321–US$1,665) [58]. Our results are somewhat sensitive to changes in VMMC effectiveness, VMMC coverage targets, time to scale-up, and VMMC cost. Nonetheless, all of the values tested for these parameters resulted in lives saved and cost savings for all countries. It is especially important to note that even if VMMC coverage is scaled up to 50% in 5 y instead of to 80%, high numbers of infections will be averted and net savings per infection averted will be obtained in all countries except Mozambique and Tanzania—the two countries where pre-scale-up coverage is higher than 50%. This is critical because even though there is no evidence available yet on the feasibility of scaling up VMMC coverage to 80%, there is evidence that VMMC coverage rates of above 50% can be reached through VMMC scale-up efforts [56]. Similar to the results reported by other authors, our results suggest that post-circumcision risk behavior change is unlikely to completely reverse the benefits of male circumcision, with the possible exception of Rwanda. In the case of Rwanda, the low incidence of HIV (0.3%) means that risk compensation associated with male circumcision could actually make the epidemic worse. In the remaining countries, the negative consequences from a 30% risk compensation would be insufficient to fully reverse the benefits of VMMC. In all countries, it is critical that VMMC programs emphasize that male circumcision is not 100% protective and that condom use and other behavioral risk reductions remain essential [8],[59]. Effective messaging in this regard is critical to ensure that men and their sexual partners do not increase their sexual risk behaviors following VMMC scale-up. This study has a number of limitations. Because this model was designed primarily for advocacy purposes, certain elements are not modeled, including treatment, a more fully articulated age structure, and force of infection, which probably leads to an overestimate of the impact of male circumcision. Another limitation is that we use pre-scale-up male circumcision coverage estimates based on men's self-reported circumcision status in household surveys. There is some evidence that uncircumcised and partially circumcised men may report being circumcised in some populations [60]. Unfortunately, there is no information available on the prevalence of this phenomenon in the countries studied. In the one country where partial circumcision is known to be widely practiced (Lesotho), we assume baseline VMMC prevalence to be at 0% rather than using the self-reported data. Additional limitations relate to our cost assumptions. Ideally, we would have obtained country-specific VMMC unit cost estimates based on the MOVE model instead of only adjusting the staff costs by country based on after-tax median monthly disposable salary. However, this model for delivering VMMC was available in only a limited number of sites. Our VMMC unit cost, which is higher than that used in previous studies [8],[11],[59],[61],[62], reflects a better understanding of the service delivery components required for such a program, including waste management and logistics associated with the scaling up of VMMC services [52]. It should also be noted that countries are procuring the same circumcision kits and are adopting the same service delivery model that was costed in this study. If possible, we would also have adjusted VMMC unit cost over time and scale [63],[64]. However, no information is currently available on how VMMC unit cost might vary over time and with scale. Another limitation is that we do not include costs associated with demand creation in our study [65]. Finally, it would have been preferable for us to obtain country-specific ART costs; however, country-specific data for the 13 countries studied were not available. HIV prevalence and incidence estimates used in the model and how they compare to the actual present and projected prevalence and incidence in each of the selected countries is another factor that affects the accuracy of our findings. A steeper decline in baseline incidence, for example, will result in fewer infections averted as a result of VMMC. Conversely, if these incidence trends are overly optimistic, then the number of infections available to be averted by VMMC may in turn be larger than estimated here. We also recognize that our modeling assumes that males seeking out VMMC services are typical of the general male population in the selected age range. If, for example, those seeking out VMMC services are in fact those who are at least risk of becoming infected (perhaps VMMC clients already disproportionately use condoms), then the benefits of VMMC are likely to be overestimated. Conversely, if those who are at most risk of infection (those with a large number of partners and/or low condom use) are disproportionately attracted to VMMC services, then the modeling presented in this paper may underestimate the value of VMMC scale-up. Given that VMMC client sexual behavior, relative to the behavior of the general male population, remains unknown, it is not possible to determine whether our projections are underestimated or overestimated. There are also a number of prevention benefits that are indirectly associated with seeking out VMMC services. These include the benefits of counseling and testing, STI treatment, and early antiretroviral treatment. For example, for those males who seek out VMMC services but find that they are already HIV-infected, there could be societal prevention benefits if these men subsequently are able to access early treatment and reduce their infectivity. Since we focus only on the direct benefits received by those receiving VMMC and do not quantify any additional benefits of counseling and testing, STI treatment, and early antiretroviral treatment as a result of seeking VMMC services, it is possible that the prevention benefits of VMMC could be underestimated. The past year has been marked by important advances in HIV prevention, including the finding that early treatment initiation reduces sexual transmission by as much as 96% in stable serodiscordant couples [66]. However, the population-level impact of treatment is not currently well known. And coverage of those eligible for antiretroviral treatment under WHO guidelines remains low, with less than half of people needing treatment having access to it in eastern and southern Africa in 2010 [67]. VMMC is a one-time surgical procedure with the promise of substantial impact on population-level HIV incidence. Its effects accrue to both men and women, and it compares favorably with other HIV prevention programs in terms of cost-effectiveness. Countries are adopting WHO/UNAIDS recommendations to incorporate VMMC within their HIV prevention portfolios. Best practices from Kenya [68], Tanzania [69], and South Africa [56] show that with government leadership, community involvement, and collaboration among partners, it is possible to scale up rapidly by implementing service delivery models that take into consideration available resources, efficiency, and quality to achieve the maximum public health impact. To ensure that high coverage rates are achievable, countries and their international partners should allocate enough resources to take advantage of the returns on investment predicted for this biomedical HIV prevention modality. Supporting Information Table S1 Model details and equations. (DOCX) Click here for additional data file.

0 comments Cited 150 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Male circumcision for the prevention of HSV-2 and HPV infections and syphilis.

Patti E Gravitt, Lawrence Moulton, M. Wawer … (2009)

Male circumcision significantly reduced the incidence of human immunodeficiency virus (HIV) infection among men in three clinical trials. We assessed the efficacy of male circumcision for the prevention of herpes simplex virus type 2 (HSV-2) and human papillomavirus (HPV) infections and syphilis in HIV-negative adolescent boys and men. We enrolled 5534 HIV-negative, uncircumcised male subjects between the ages of 15 and 49 years in two trials of male circumcision for the prevention of HIV and other sexually transmitted infections. Of these subjects, 3393 (61.3%) were HSV-2-seronegative at enrollment. Of the seronegative subjects, 1684 had been randomly assigned to undergo immediate circumcision (intervention group) and 1709 to undergo circumcision after 24 months (control group). At baseline and at 6, 12, and 24 months, we tested subjects for HSV-2 and HIV infection and syphilis, along with performing physical examinations and conducting interviews. In addition, we evaluated a subgroup of subjects for HPV infection at baseline and at 24 months. At 24 months, the cumulative probability of HSV-2 seroconversion was 7.8% in the intervention group and 10.3% in the control group (adjusted hazard ratio in the intervention group, 0.72; 95% confidence interval [CI], 0.56 to 0.92; P=0.008). The prevalence of high-risk HPV genotypes was 18.0% in the intervention group and 27.9% in the control group (adjusted risk ratio, 0.65; 95% CI, 0.46 to 0.90; P=0.009). However, no significant difference between the two study groups was observed in the incidence of syphilis (adjusted hazard ratio, 1.10; 95% CI, 0.75 to 1.65; P=0.44). In addition to decreasing the incidence of HIV infection, male circumcision significantly reduced the incidence of HSV-2 infection and the prevalence of HPV infection, findings that underscore the potential public health benefits of the procedure. (ClinicalTrials.gov numbers, NCT00425984 and NCT00124878.) 2009 Massachusetts Medical Society

0 comments Cited 140 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa.

Pascale Lissouba, M Nieuwoudt, Joelle Sobngwi-Tambekou … (2009)

A causal association links high-risk human papillomavirus (HR-HPV) and cervical cancer, which is a major public health problem. The objective of the present study was to investigate the association between male circumcision (MC) and the prevalence of HR-HPV among young men. We used data from a MC trial conducted in Orange Farm, South Africa, among men aged 18-24 years. Urethral swab samples were collected during a period of 262 consecutive days from participants in the intervention (circumcised) and control (uncircumcised) groups who were reporting for a scheduled follow-up visit. Swab samples were analyzed using polymerase chain reaction. HR-HPV prevalence rate ratios (PRRs) were assessed using univariate and multivariate log Poisson regression. In an intention-to-treat analysis, the prevalences of HR-HPV among the intervention and control groups were 14.8% (94/637) and 22.3% (140/627), respectively, with a PRR of 0.66 (0.51-0.86) (P = .002). Controlling for propensity score and confounders (ethnic group, age, education, sexual behavior [including condom use], marital status, and human immunodeficiency virus status) had no effect on the results. This is the first randomized controlled trial to show a reduction in the prevalence of urethral HR-HPV infection after MC. This finding explains why women with circumcised partners are at a lower risk of cervical cancer than other women.

0 comments Cited 75 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Charlene S. Dezzutti: Role: Editor

Journal

Journal ID (nlm-ta): PLoS One

Journal ID (iso-abbrev): PLoS ONE

Journal ID (publisher-id): plos

Journal ID (pmc): plosone

Title: PLoS ONE

Publisher: Public Library of Science (San Francisco, CA USA )

ISSN (Electronic): 1932-6203

Publication date (Electronic): 13 July 2016

Publication date Collection: 2016

Volume: 11

Issue: 7

Electronic Location Identifier: e0153363

Affiliations

[1 ]Health Policy Project, Avenir Health, Glastonbury, Connecticut, United States of America

[2 ]Health Policy Project, Futures Group, Washington, District of Columbia, United States of America

[3 ]Tanzania National AIDS Control Program, Dar es Salaam, Tanzania

[4 ]Independent Consultant, Dar es Salaam, Tanzania

[5 ]U. S. Agency for International Development, Dar es Salaam, Tanzania

[6 ]Jhpiego, Dar es Salaam, Tanzania

[7 ]Joint United Nations Programme on HIV/AIDS, Dar es Salaam, Tanzania

[8 ]United States Department of Defense, Dar es Salaam, Tanzania

[9 ]Office of the U.S. Global AIDS Coordinator, Washington, District of Columbia, United States of America

[10 ]U. S. Agency for International Development, Washington, District of Columbia, United States of America

University of Pittsburgh, UNITED STATES

Author notes

Competing Interests: The authors have declared that no competing interests exist.

Conceived and designed the experiments: KK EN. Performed the experiments: KK. Analyzed the data: KK NP JL BF EM HM JMJ EB MP DK IS DC EN. Contributed reagents/materials/analysis tools: JL BF EM HM JMJ EB MP DK IS. Wrote the paper: KK NP JL BF HM JMJ EB MP DK IS DC EN.

* E-mail: kkripke@ 123456avenirhealth.org

Author information

Emmanuel Njeuhmeli http://orcid.org/0000-0001-5370-4827

Article

Publisher ID: PONE-D-15-49240

DOI: 10.1371/journal.pone.0153363

PMC ID: 4943708

PubMed ID: 27410384

SO-VID: 7e2cbe67-25a8-4e42-b22c-93dff73a7a38

License:

This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

History

Date received : 11 November 2015

Date accepted : 29 March 2016

Page count

Figures: 5, Tables: 1, Pages: 14

Funding

Funded by: funder-id http://dx.doi.org/10.13039/100000200, United States Agency for International Development;

Award ID: AID-OAA-A-10-00067

Funded by: funder-id http://dx.doi.org/10.13039/100000200, United States Agency for International Development;

Award ID: AID-OAA-14-00026

This work was funded by the President's Emergency Plan for AIDS Relief (PEPFAR) through the United States Agency for International Development (USAID) | Health Policy Project, Agreement No. AID-OAA-A-10-00067, beginning September 30, 2010. The Health Policy Project is implemented by Futures Group, in collaboration with Plan International USA, Avenir Health (formerly Futures Institute), Partners in Population and Development, Africa Regional Office (PPD ARO), Population Reference Bureau (PRB), RTI International, and the White Ribbon Alliance for Safe Motherhood (WRA). The funder was involved in study design, analysis of data, decision to publish, and preparation of the manuscript. The findings and conclusions in this paper do not necessarily represent the views or positions of USAID or the U.S. Government.

Custom metadata

Data Availability All relevant data are within the paper and its supporting information files.

The Economic and Epidemiological Impact of Focusing Voluntary Medical Male Circumcision for HIV Prevention on Specific Age Groups and Regions in Tanzania

Read this article at

Abstract

Background

Methods and Findings

Conclusions

Related collections

PLOS Climate

Most cited references 9

Voluntary Medical Male Circumcision: Modeling the Impact and Cost of Expanding Male Circumcision for HIV Prevention in Eastern and Southern Africa

Male circumcision for the prevention of HSV-2 and HPV infections and syphilis.

Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa.

Author and article information

Contributors

Journal

Affiliations

Author notes

Author information

Article

History

Page count

Funding

Categories

Custom metadata

Comments

Comment on this article

Similar content 702

Cited by 10

Most referenced authors 152